All news (page 30)

• 

  30 April 2026

  Avantium completes titanium weld repairs at FDCA flagship plant

  Weld repairs completed with engineering partners. Commissioning continues: utilities and sugar dehydration online; oxidation and purification in final start-up. Commercial sales expected H2 2026
• 

  30 April 2026

  Trinseo Q1 2026 Results

  Q1 sales $725M (-8%); net loss $116M; Adjusted EBITDA $53M; Free Cash Flow -$244M; ending cash/liquidity $114M; added $50M to revolver; charges $31M
• 

  30 April 2026

  Petrobras posts 1Q26 own production record of 3.23 MMboed

  Ramp-up of multiple FPSOs and 10 new wells drove production gains (3.7% QoQ, 16.1% YoY); operated production 4.65 MMboed. Refining utilization, S10 diesel output and logistics records; LPG imports fell.
• 

  30 April 2026

  Petrobras resumes urea production at Ansa in Araucária, PR

  Urea output resumed after 2020 hibernation following R$870M reactivation; mobilization created 2,000 jobs and ~700 ongoing; restart after ARLA‑32 and ammonia tests strengthens domestic supply
• 

  30 April 2026

  Elkem completes sale of Silicones division to Bluestar and redeems Bluestar shares

  Registered share capital is NOK 1,505,514,210 (301,102,842 shares, NOK 5 par). Board and Nomination Committee changes took effect; seller no longer represented.
• 

  30 April 2026

  Symrise expands Food & Beverage capabilities in Barcelona

  Upgraded site adds powdered production and large-scale mixer, modern application and quality labs for faster prototyping, smoother scale-up, local technical support, and solar/water reuse.

• 

  30 April 2026

  Umicore Q1 momentum points to ~€1bn adjusted EBITDA in 2026

  Strong Q1: Catalysis and Recycling strong; Specialty led by cobalt; CAM volumes modest, take‑or‑pay compensation; anode JV in place; capex up; leverage <2x
• 

  30 April 2026

  Kemira Oyj: Share repurchases, week 18/2026

  Repurchased 282,380 shares (Apr 27–30) at avg €17.375, total €4,906,349.13; post-buyback treasury holdings 3,783,343 shares. Buyback part of program running until Sept 20, 2026.
• 

  30 April 2026

  OMV Petrom Q1 2026 Results

  Strong asset output; Clean CCS EBIT 1.5bn lei (+16%); net income 1bn lei (-4%); CAPEX 1.6bn lei (+14%); state contributions 4.1bn lei (+9%); E&P down, production -3.1%; refining margin and power output rose
• 

  30 April 2026

  Borouge Q1 2026: $156M Net Profit on Operational Resilience

  Q1 revenue $1.2B; production 1.21Mt (98% capacity), sales 1.09Mt. 61% of March output rerouted via alternative logistics. Prices rose 62% in March. H2 2025 dividend $658M; merger forms global polyolefins platform.
• 

  30 April 2026

  BASF Q1 2026: resilient performance

  Solid volume growth offset currency headwinds; EBITDA before special items €2.4bn (vs €2.5bn). Sales slightly down; free cash flow -€1.375bn. Dividend €2.25; outlook unchanged.
• 

  30 April 2026

  Lhyfe to supply green hydrogen to BMW Group’s Steyr R&D centre

  Multi-year deal to supply green hydrogen to an Austrian R&D site for development and validation of third-gen fuel-cell systems; first Austrian deliveries via bulk transport; RFNBO-certified.
• 

  30 April 2026

  Roche to present ophthalmology portfolio data at ARVO 2026

  ARVO 2026: real‑world data show Vabysmo reduces retinal fluid in nAMD/DME; Susvimo enables sustained delivery with lower treatment burden; early vamikibart IL‑6 results; 45+ abstracts.
• 

  30 April 2026

  PETRONAS, ENEOS Xplora: ENEOS to re-enter MLNG Tiga with 10% stake

  Reaffirmed long-term partnership strengthens energy security and steady LNG supply to Asia, notably Japan; underscores asset resilience and investor confidence in Malaysia’s LNG sector.
• 

  30 April 2026

  Technip Energies Q1 2026 Results

  >€6bn orders, backlog >€20bn; revenue €1.8bn, EBITDA €149m, FCF €132m (89% conv). Middle East disruptions defer €500–600m; Project Delivery guidance cut to €5.7–6.3bn; TP&S steady.
• 

  30 April 2026

  Moody’s Affirms ORLEN A3 Rating

  Moody's notes strong liquidity and baa2 BCA with stable outlook. Solid balance sheet and cash flows can fund capex and dividends. Diverse supply, flexible trading and 2026 projects boost resilience.
• 

  30 April 2026

  Eli Lilly Q1 2026: Revenue up 56%, raises full‑year guidance

  EPS jumped ~170% reported (~156% non‑GAAP); volume growth offset lower realized prices; FDA approved oral GLP‑1 Foundayo; positive Phase‑3 readouts; four acquisitions announced
• 

  30 April 2026

  Merck & Co Q1 2026 Results — Sales Growth, Regulatory Approvals and Clinical Milestones

  Q1 revenue $16.3B; KEYTRUDA $8.0B. GAAP loss $1.72/sh, non-GAAP loss $1.28/sh after $9.0B Cidara charge. Announced Terns acquisition; raised 2026 sales to $65.8-67.0B and non-GAAP EPS $5.04-5.16
• 

  30 April 2026

  OMV: Clean CCS operating result ~EUR 1.0bn in Q1 2026

  Q1: operating cash flow €776m (€1,624m excl NWC, +20%); net income €323m; leverage 17%. Energy down, Fuels flat, Chemicals up on Borealis reclass. and higher polyolefin margins; Borouge closed
• 

  30 April 2026

  TotalEnergies and Nextnorth begin construction of 440 MW solar plant in Philippines

  Financial close; construction begun on 440 MWp solar in Ilagan, Isabela. Online end‑2027. Produces 13.5 TWh/20 yrs; >50% sold via long‑term C&I contracts, remainder to grid via govt auction. $300M
• 

  29 April 2026

  Biosimilars: stricter expectations for elastomeric closures

  Originator-level assessment required (functionality, E&L, CCI). Supplier data can't replace system-level testing. Risks: format migration, dual-market filings. Adopt platform approach; decide early.
• 

  29 April 2026

  Genentech to present ophthalmology data at ARVO 2026

  ARVO presentations: real-world Vabysmo data show retinal drying in wet AMD/DME; Susvimo demonstrates sustained delivery and reduced treatment burden; vamikibart shows early efficacy; >45 abstracts
• 

  29 April 2026

  SABIC Q1 2026 results

  Q1: adjusted EBITDA +25% to SAR4.15bn; revenue -6% to SAR26.15bn; adjusted net income SAR816m; realized $220m recurring EBITDA savings; divestments announced; urea capacity could rise 54%
• 

  29 April 2026

  Novo Nordisk: Denecimig (Mim8) reduces annualised bleeding rate in haemophilia A regardless of inhibitor status

  Denecimig (Mim8) cut annualised bleeding rates in haemophilia A (with/without inhibitors) in Phase 3 FRONTIER2 for once-monthly/weekly dosing; well tolerated, no thromboembolic events
• 

  29 April 2026

  Evonik opens PEEK magnet‑wire lab in China

  China lab develops PEEK rectangular magnet-wire for NEV motors: extrusion/coating, dimensional checks and reliability tests (BDV, PDIV, corona, oil-aging) to accelerate product development.
• 

  29 April 2026

  GSK Q1 2026 — Specialty Medicines Drive Growth

  Q1 sales £7.6bn (+5% CER); Specialty Medicines £3.2bn (+14%). Core operating profit +10%, Core EPS +9%. Strong cash generation; 17p Q1 dividend. 2026 guidance and >£40bn 2031 target reaffirmed.
• 

  29 April 2026

  MAIRE Q1 2026: Revenues & EBITDA up; 2026 guidance confirmed

  Q1: Net income €76.7m (+19.9%); adjusted net cash €396.1m; order intake €4.78bn; backlog €15.73bn; Nextchem revenue +46%; record dividend €0.585/share
• 

  29 April 2026

  INEOS Acetyls and Sandpiper partner on 1.1 MTPA low‑carbon methanol plant in Texas City

  FEED starts Q2 2026; FID targeted 2027; first production 2030. ~$1.7B capex. Up to 300,000 t/y to Acetic Acid. ~1,500 construction jobs, 25 permanent. CCS targets 97% capture.
• 

  29 April 2026

  Exolum to develop Avonmouth CO2 storage hub with Severnside Carbon

  New Avonmouth CO2 storage and shipping terminal will open by 2031, handling up to 6Mt/yr via rail and ship to serve southwest England, Midlands and South Wales and enable CCUS access.
• 

  29 April 2026

  UPM approves Plywood demerger to create listed WISA Group

  Board approved plan to spin off a business into a new listed company; EGM approval pending; 1:1 share distribution; target completion Oct 31, 2026; listing expected early Nov 2026.